Buchumschlag

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy: a retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who relapse after transplant is poor. We present the results of a retros...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: González Barca, Eva (VerfasserIn) , Dreger, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2020
In: Bone marrow transplantation
Year: 2019, Jahrgang: 55, Heft: 2, Pages: 393-399
ISSN:1476-5365
DOI:10.1038/s41409-019-0650-x
Online-Zugang:Verlag, Volltext: https://doi.org/10.1038/s41409-019-0650-x
Verlag: https://www.nature.com/articles/s41409-019-0650-x
Volltext
Verfasserangaben:E. González-Barca, A. Boumendil, D. Blaise, M. Trněný, T. Masszi, H. Finel, M.G. Michieli, J.T. Bittenbring, G. Gritti, J. A. Snowden, M. Bishton, B. Bruno, S. González de Villambrosia, A. Janikova, X. Leleu, A. Anagnostopoulos, X. Poiré, M. Crysandt, Z.N. Özkurt, E. Vandenberghe, M. Itälä-Remes, J.Y. Cahn, E. Jantunen, W. Schroyens, J. Maertens, A. Esquirol, P. Dreger, S. Montoto, A. Sureda
Beschreibung
Zusammenfassung:Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who relapse after transplant is poor. We present the results of a retrospective study of 256 adult patients reported to the EBMT registry with DLBCL who relapsed after auto-HSCT performed between 2003 and 2013, and who received active salvage strategies. One hundred and fifty-four (60%) were male; median age was 53 years. Median time to relapse was 7 months, 65% relapsed during the first year. Overall response rate after salvage therapy was 46%. Median follow-up after first salvage therapy was 40 months (IQR 23-63 months). Overall survival (OS) at 3 years was 27% (95% CI 22-33). OS at 3 years of patients relapsing longer than 1 year after auto-HSCT was 41% (95% CI 31-53) compared with 20% (95% CI 14-24) in those who relapsed in less than 1 year. Eighty-two patients (32%) had a second HSCT, an allogeneic HSCT (allo-HSCT) in 69 cases, at a median time of 6.5 months after relapse. OS at 3 years after allo-HSCT was 36% (95% CI 25-51). In conclusion, the prognosis of patients with DLBCL that relapse after auto-HSCT is dismal. Patients who relapse in less than 1 year remain an unmet need, and should be considered for CAR T cell therapy or clinical trials. Patients who relapse after 1 year can be rescued with salvage therapies and a second HSCT. These results provide a benchmark to compare data of new prospective studies.
Beschreibung:Published online: 20 September 2019
Gesehen am 12.03.2020
Beschreibung:Online Resource
ISSN:1476-5365
DOI:10.1038/s41409-019-0650-x

Ähnliche Einträge